Suppr超能文献

流感、肺炎和新冠病毒感染住院后发生主要动脉和静脉血栓性疾病的风险:威尔士260万人的全人群队列研究

Risks of major arterial and venous thrombotic diseases after hospitalisation for influenza, pneumonia, and COVID-19: A population-wide cohort in 2.6 million people in Wales.

作者信息

Keene Spencer, Abbasizanjani Hoda, Torabi Fatemeh, Knight Rochelle, Walker Venexia, Raffetti Elena, Cezard Genevieve, Ip Samantha, Sampri Alexia, Bolton Thomas, Denholm Rachel, Khunti Kamlesh, Akbari Ashley, Quint Jennifer, Denaxas Spiros, Sudlow Cathie, Di Angelantonio Emanuele, Sterne Jonathan A C, Wood Angela, Whiteley William N

机构信息

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK; NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge, Cambridge, UK.

Population Data Science, Swansea University Medical School, Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, UK.

出版信息

Thromb Res. 2025 Jan;245:109213. doi: 10.1016/j.thromres.2024.109213. Epub 2024 Nov 19.

Abstract

OBJECTIVE

Pneumonia, influenza, COVID-19, and other common infections might increase the risk of thrombotic events acutely through an interaction between inflammation and the thrombotic system. The long-term risks of arterial and venous thrombotic events following hospitalisation for COVID-19 and hospitalisation for pneumonia or influenza are unclear.

MATERIALS AND METHODS

In a population-wide cohort of linked Welsh health data of adults, we calculated the incidence of arterial and venous thrombosis after hospitalisation for COVID-19 (2020-2021). We then compared this post-hospitalisation incidence with the incidence prior to COVID-19 hospitalisation in the same individuals, and with the incidence in individuals who were never hospitalised for COVID-19. We then repeated this analysis for hospitalisation for pneumonia or influenza in a separate cohort (2016-2019). We estimated adjusted hazard ratios (aHRs) in separate time periods starting from the date of the first infection that resulted in hospitalisation (day 0, 1 to 7 days, 2 to 4 weeks, 5 to 16 weeks, and 17 to 75 weeks) using time-varying Cox regression. Confounders included age, sex, smoking status, obesity, deprivation (fifths of Welsh Index of Multiple Deprivation), rural or urban setting, care home attendance, Elixhauser comorbidity index, surgery in the last year, medications (e.g. lipid-lowering and antiplatelet/anticoagulant use), hypertension and/or hypertensive medication use, and past medical history of chronic kidney disease, diabetes, chronic obstructive pulmonary disease, dementia, cancer, or any CVD.

RESULTS

For the first arterial thrombosis, the aHRs were 3.80 (95 % CI: 2.50-5.77) between days 1-7, 5.24 (4.21-6.51) between weeks 2-4, 2.12 (1.72-2.60) between weeks 5-16, and 1.60 (1.38-1.86) between weeks 17-75 after hospitalisation for COVID-19. The corresponding aHRs after hospitalisation for pneumonia/influenza were: 5.42 (4.35-6.75), 3.87 (3.32-4.49), 1.96 (1.74-2.21), and 1.41 (1.30-1.53). For first venous thrombosis, aHRs were 7.47 (3.56-15.7) between days 1-7, 22.6 (17.5-29.1) between weeks 2-4, 6.58 (4.98-8.68) between weeks 5-16, and 2.25 (1.67-3.02) between weeks 17-75 after hospitalisation for COVID-19. The corresponding aHRs after hospitalisation for pneumonia/influenza were: 15.1 (10.3-22.0), 11.8 (9.23-15.1), 5.80 (4.75-7.08), and 1.89 (1.57-2.29). Excess risk was highest in individuals aged ≥60 years, in whom we estimated 2,700 and 2,320 additional arterial and 1,270 and 840 additional venous events after 100,000 hospitalisations for COVID-19 and pneumonia/influenza, respectively.

CONCLUSIONS

Both hospitalisation for COVID-19 and pneumonia/influenza increase the risk of arterial and venous thrombosis. Preventative healthcare policies are needed for cardiovascular risk factor management, vaccination, and anticoagulation in high-risk patients with hospitalised or severe infections.

摘要

目的

肺炎、流感、新冠病毒病及其他常见感染可能通过炎症与血栓形成系统之间的相互作用,急性增加血栓形成事件的风险。新冠病毒病住院治疗、肺炎或流感住院治疗后发生动脉和静脉血栓形成事件的长期风险尚不清楚。

材料与方法

在一项将威尔士成年人健康数据相链接的全人群队列研究中,我们计算了新冠病毒病住院治疗(2020 - 2021年)后动脉和静脉血栓形成的发生率。然后,我们将该住院后发生率与同一人群中新冠病毒病住院治疗前的发生率以及从未因新冠病毒病住院治疗的个体的发生率进行比较。然后,我们在一个单独的队列(2016 - 2019年)中对肺炎或流感住院治疗重复了这一分析。我们使用时变Cox回归,在从首次导致住院治疗的感染日期开始的不同时间段(第0天、1至7天、2至4周、5至16周以及17至75周)估计调整后的风险比(aHRs)。混杂因素包括年龄、性别、吸烟状况、肥胖、贫困程度(威尔士多重贫困指数五分位数)、农村或城市环境、养老院入住情况、埃利克斯豪泽合并症指数、过去一年的手术史、药物治疗(如降脂及抗血小板/抗凝药物使用)、高血压和/或高血压药物使用,以及慢性肾病、糖尿病、慢性阻塞性肺疾病、痴呆、癌症或任何心血管疾病的既往病史。

结果

对于首次动脉血栓形成,新冠病毒病住院治疗后第1 - 7天的aHR为3.80(95%CI:2.50 - 5.77);第2 - 4周为5.24(4.21 - 6.51);第5 - 16周为2.12(1.72 - 2.60);第17 - 75周为1.60(1.38 - 1.86)。肺炎/流感住院治疗后的相应aHR分别为:5.42(4.35 - 6.75)、3.87(3.32 - 4.49)、1.96(1.74 - 2.21)和1.41(1.30 - 1.53)。对于首次静脉血栓形成,新冠病毒病住院治疗后第1 - 7天的aHR为7.47(3.56 - 15.7);第2 - 4周为22.6(17.5 - 29.1);第5 - 16周为6.58(4.98 - 8.68);第17 - 75周为2.25(1.67 - 3.02)。肺炎/流感住院治疗后的相应aHR分别为:15.1(10.3 - 22.0)、11.8(9.23 - 15.1)、5.80(4.75 - 7.08)和1.89(1.57 - 2.29)。≥60岁的个体额外风险最高,在100,000例新冠病毒病住院治疗和肺炎/流感住院治疗后,我们估计分别有2700例和2320例额外的动脉事件以及1270例和840例额外的静脉事件。

结论

新冠病毒病住院治疗以及肺炎/流感住院治疗均会增加动脉和静脉血栓形成的风险。对于住院或严重感染的高危患者,需要制定预防性医疗保健政策,以进行心血管危险因素管理、疫苗接种和抗凝治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验